COVID-19 Antibody Testing
Monday, May 18, 2020
Retroactive to March 18, 2020, TRICARE will cover medically-necessary COVID-19 antibody (serology) testing. There are no authorization requirements; however, to be considered for coverage, antibody testing must be rendered to diagnose and/or treat beneficiaries, and meet Families First Coronavirus Response Act (FFCRA) criteria. As with COVID-19 diagnostic tests, all beneficiary copayments and cost-shares for covered COVID-19 antibody tests are waived. Find current benefit details on our COVID-19 Testing page.
Current Procedural Terminology (CPT®) codes for antibody testing include 86328 and 86769 for dates of service on or after April 10, 2020. Tests that are not medically necessary for the diagnosis or treatment of patients are not covered under TRICARE. This includes serology testing performed:
- on asymptomatic patients;
- to satisfy patient curiosity;
- to determine a patient’s ability to return to work or school;
- to determine a donor’s ability to donate blood or plasma; and/or
- as part of epidemiological research, surveillance studies or for other public health reasons.
We appreciate your patience as we work with the Defense Health Agency on finalizing system updates required for the release of pending COVID-19 diagnostic tests and now COVID-19 antibody testing claims. Find the latest updates on our COVID-19 resource page and www.health.mil/coronavirus.